Johnson & Johnson (JNJ) Stock: Price, Forecast & Analyst Target
Johnson & Johnson (JNJ) — MoonshotScore 89/100 (Exceptional band), calculated Oct 7, 2026. Price $254.78 (+0.73%), as of the Oct 6, 2026 trading session; market cap $614B. Expected results Oct 13, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 29.58× (market value Oct 6, 2026; cash Jun 28, 2026) · expected results Oct 13, 2026
Johnson & Johnson · JNJ · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-13: Johnson & Johnson combines prescription medicines with devices used in surgery, orthopaedics, vision care and interventional treatment. Its scale matters less than whether rising sales can keep translating into durable operating profit and cash generation across Innovative Medicine and MedTech.
Price as of Oct 6, 2026
Key Statistics
MoonshotScore v2 · Johnson & Johnson (JNJ)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $25.31B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- expected results Oct 13, 2026
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional |
The score moved from 90 in the stored Oct 6, 2026 snapshot to 89 in the current publication computed Oct 7, 2026 (-1); the largest pillar moves were Growth Durability -1 and Momentum +1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $254.78 | |
| Change on the day | +0.73% | |
| 52-week range | $182.94–$281.07 | |
| Market capitalisation | $614B | |
| Price / earnings (trailing) | 29.45 | |
| Shares traded on the day | 5.66M | |
| Beta (volatility vs the S&P 500) | 0.24 | |
| Dividends per share (last 12 months) | $5.28 | |
| Dividend yield (last 12 months) | 2.07% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Building on our recent acquisition of Ambrx, we also announced plans to acquire Firefly Bio, adding another antibody platform that strengthens our leadership in next-generation oncology innovation. We expect the transaction to close during the third quarter.
Joaquin Duato · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Johnson & Johnson (JNJ): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 29, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 7, 2026, except a card that shows its own read date.
Watch the JNJ film — every key number, told as a short cinematic story
~2 min · open the film
What is Johnson & Johnson (JNJ), and what does it report?
Short answer · as of
Johnson & Johnson is a healthcare holding company, not merely a diversified drugmaker. Innovative Medicine sells therapies spanning oncology, immunology, neuroscience and other disease areas, while MedTech supplies products tied to procedures and clinical care.
Research dated 2026-09-13.
Johnson & Johnson is a healthcare holding company, not merely a diversified drugmaker. Innovative Medicine sells therapies spanning oncology, immunology, neuroscience and other disease areas, while MedTech supplies products tied to procedures and clinical care.
Innovative Medicine contributes more revenue, but consolidated sales and profit blend pharmaceutical demand with activity in surgery, orthopaedics, vision and interventional treatment. That reporting shape means a movement in the company total may originate from very different product and customer dynamics.
What do the latest results show for Johnson & Johnson (JNJ)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $25.31B.
Research dated 2026-09-13.
The latest quarter showed sequential gains in revenue, gross profit, operating profit, net income and diluted earnings. Revenue and the earnings measure compared with consensus also exceeded expectations, extending a record of meeting or surpassing the displayed estimates.
Cash generation improved from the preceding quarter, although it remained below stronger periods in the recent series. Separately, management said the planned Firefly Bio acquisition would add an antibody platform and reinforce the oncology portfolio; that is a strategic claim, not an explanation for the reported improvement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $25.31B Jun 28, 2026
- Latest quarter · R&D
- $3.65B Jun 28, 2026
- Latest quarter · SG&A
- $6.43B Jun 28, 2026
- Latest quarter · FMP standardized operating result
- $7.17B Jun 28, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 28, 2026 | $25.31B | $3.65B | $6.43B | $7.17B |
| Mar 29, 2026 | $24.06B | $3.53B | $6.03B | $6.39B |
| Dec 28, 2025 | $24.56B | $4.25B | $6.75B | $5.59B |
| Sep 28, 2025 | $23.99B | $3.67B | $5.92B | $7.10B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $25.31B Jul 15, 2026
- Latest report · revenue estimate
- $25.06B Jul 15, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 15, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 15, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 15, 2026 | $25.31B | $25.06B | $2.9000 | $2.8400 |
| Apr 14, 2026 | $24.06B | $23.61B | $2.7000 | $2.6800 |
| Jan 21, 2026 | $24.56B | $24.15B | $2.4600 | $2.4600 |
| Oct 14, 2025 | $23.99B | $23.76B | $2.8000 | $2.7600 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $25.31B | $5.53B | $2.27 (diluted) |
| Q1 FY2026 | $24.06B | $5.24B | $2.14 (diluted) |
| Q4 FY2025 | $24.56B | $5.12B | $2.10 (diluted) |
| Q3 FY2025 | $23.99B | $5.15B | $2.12 (diluted) |
What are the financial strengths and risks for Johnson & Johnson (JNJ)?
Short answer
Cash and short-term investments were $20.76B at the Jun 28, 2026 balance-sheet date. Operating cash flow was $4.71B for the quarter ended Jun 28, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Johnson & Johnson remains profitable at substantial gross and operating margins, and every displayed quarter generated positive operating cash flow after funding ongoing research activity. Recent cash generation also exceeded capital spending, while the financial quality and distress screens remain favorable.
Liquidity deserves a more qualified reading. Cash and short-term investments sit below total debt, quick assets do not cover current obligations, and the cash balance has retreated from its recent peak. Dividend payments continued at a higher per-share rate than earlier listed payments, leaving cash conversion, leverage and distributions linked through capital allocation.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $4.71B Jun 28, 2026
- Previous quarter · operating cash flow
- $2.51B Mar 29, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 28, 2026 | $4.71B | −$1.32B |
| Mar 29, 2026 | $2.51B | −$1.05B |
| Dec 28, 2025 | $7.31B | −$1.84B |
| Sep 28, 2025 | $9.17B | −$788.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Johnson & Johnson (JNJ)?
Short answer · as of
The next earnings report is expected on Oct 13, 2026.
Research dated 2026-09-13.
The next earnings release should be read against the latest high revenue base and the established pattern of consensus outperformance. The useful checks are whether operating profit advances with sales, whether operating cash flow continues recovering, and whether cash stabilizes relative to debt.
Firefly Bio adds another checkpoint: completion would move the antibody platform from announced intent into the portfolio. Longer-range forecasts anticipate continuing revenue and earnings expansion, but analyst participation becomes progressively thinner, so execution across the operating segments matters more than the distant consensus path.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Building on our recent acquisition of Ambrx, we also announced plans to acquire Firefly Bio, adding another antibody platform that strengthens our leadership in next-generation oncology innovation. We expect the transaction to close during the third quarter.
Joaquin Duato ·
How does Johnson & Johnson compare with its peers?
Short answer
Johnson & Johnson's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a pure pharmaceutical company, Johnson & Johnson carries direct exposure to procedure volumes through surgery, orthopaedics, vision and interventional products. Compared with a pure medical-device company, its larger revenue engine is Innovative Medicine. Consolidated results therefore combine therapeutic product cycles with procedure-linked demand, and weakness in one business need not describe the other.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1157.49 Oct 6, 2026 | $1.09T | 97 5-pillar Oct 7, 2026 | |
| $37.53 Oct 6, 2026 | $167B | 91 5-pillar Oct 7, 2026 | |
| $59.59 Oct 6, 2026 | $120B | 91 5-pillar Oct 7, 2026 | |
| Johnson & Johnson (JNJ) — this page | $254.78 | $614B | 89 |
| $46.60 Oct 6, 2026 | $93.4B | 87 5-pillar Oct 7, 2026 | |
| $158.61 Oct 6, 2026 | $246B | 85 5-pillar Oct 7, 2026 | |
| $140.79 Oct 6, 2026 | $268B | 84 5-pillar Oct 7, 2026 | |
| $402.60 Oct 6, 2026 | $217B | 84 5-pillar Oct 7, 2026 | |
| $39.56 Oct 6, 2026 | $95.0B | 83 5-pillar Oct 7, 2026 | |
| $266.79 Oct 6, 2026 | $471B | 78 5-pillar Oct 7, 2026 | |
| $141.93 Oct 6, 2026 | $351B | 74 5-pillar Oct 7, 2026 | |
| $376.32 Oct 6, 2026 | $340B | 74 5-pillar Oct 7, 2026 | |
| $27.48 Oct 6, 2026 | $157B | 68 5-pillar Oct 7, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $255.00 – $320.00
- Consensus target
- $286.53
- Median target
- $282.00
Consensus record · Captured .
Measured against a quoted price of $254.78 (as of Oct 6, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 46
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 10
- Other transactions
- 36
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 74.5% Period end Jun 30, 2026
- Previous quarter · ownership
- 73.1% Prior to period end Jun 30, 2026
- Reporting holders
- 4,810 Period end Jun 30, 2026
- Previous quarter · holders
- 4,764 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 212,098,264 |
| Vanguard Capital Management LLC | 157,226,374 |
| State Street Corp | 133,776,025 |
| Vanguard Portfolio Management LLC | 64,370,816 |
| Geode Capital Management, LLC | 59,086,417 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
JNJ Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why is Johnson & Johnson more than a drugmaker?
Innovative Medicine is the larger segment, but MedTech also sells products used in surgery, orthopaedics, vision care and interventional treatment. The company therefore participates in medicine demand and procedure-linked healthcare spending.
Which Johnson & Johnson business contributes more revenue?
Innovative Medicine contributes more revenue than MedTech. Its portfolio spans oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic care, and pulmonary hypertension.
How does MedTech change Johnson & Johnson’s business mix?
MedTech adds products whose use is tied to clinical procedures and surgical activity, creating demand drivers distinct from prescription medicines. That makes the consolidated revenue line a blend of therapy uptake and healthcare procedure activity.
What would Firefly Bio add to Johnson & Johnson?
Management says the planned acquisition would add another antibody platform and strengthen next-generation oncology work. The immediate point to watch is whether the transaction closes and moves from planned expansion into the operating portfolio.
What is the JNJ stock price today?
The last price recorded on this page for Johnson & Johnson (JNJ) is $254.78, as of the Oct 6, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the JNJ price target?
The analyst consensus price target for Johnson & Johnson (JNJ) is $286.53 (range $255.00 to $320.00, median $282.00), per FMP data captured Oct 7, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are JNJ's next earnings?
The next earnings date listed on this page for Johnson & Johnson (JNJ) is Oct 13, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (84 figures)
The 84 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Joaquin Duato (Jul 15, 2026): Building on our recent acquisition of Ambrx, we also announced plans to acquire Firefly Bio, adding another antibody platform that strengthens our leadership in next-generation oncology innovation. We expect the transaction to close during the third quarter. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | ONE Johnson & Johnson PLZ, NEW Brunswick, NJ, 08933 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "One Johnson & Johnson Plaza, New Brunswick, NJ, 08933, US". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $254.78 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-07T00:14:20.351Z. | |
px.change | Change on the day | +0.73% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $614B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-06. FMP quote timestamp: 2026-10-06T20:00:02.000Z. Captured from FMP at 2026-10-07T00:14:18.500Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.85 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $25.31B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $182.94–$281.07 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 29.45 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5.66M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Joaquin Duato | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 141,700 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2022 through FY2025: FY2022 revenue $78.74B, net result $20.88B; FY2023 revenue $85.16B, net result $35.15B; FY2023 revenue $79.99B, net result $17.94B; FY2024 revenue $88.82B, net result $14.07B; FY2025 revenue $94.19B, net result $26.80B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Med Tech $33.79B · Innovative Medicine $60.40B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 67.9% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-28.revenue_k | Revenue — period end 2026-06-28 | $25.31B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.rd_k | R&D — period end 2026-06-28 | $3.65B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.sga_k | SG&A — period end 2026-06-28 | $6.43B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.operating_result_k | FMP standardized operating result — period end 2026-06-28 | $7.17B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.revenue_k | Revenue — period end 2026-03-29 | $24.06B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.rd_k | R&D — period end 2026-03-29 | $3.53B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.sga_k | SG&A — period end 2026-03-29 | $6.03B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.operating_result_k | FMP standardized operating result — period end 2026-03-29 | $6.39B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.revenue_k | Revenue — period end 2025-12-28 | $24.56B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.rd_k | R&D — period end 2025-12-28 | $4.25B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.sga_k | SG&A — period end 2025-12-28 | $6.75B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.operating_result_k | FMP standardized operating result — period end 2025-12-28 | $5.59B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.revenue_k | Revenue — period end 2025-09-28 | $23.99B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.rd_k | R&D — period end 2025-09-28 | $3.67B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.sga_k | SG&A — period end 2025-09-28 | $5.92B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.operating_result_k | FMP standardized operating result — period end 2025-09-28 | $7.10B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-15.revenue_actual | Revenue · reported — report date 2026-07-15 | $25.31B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-15.revenue_estimated | Revenue · estimate — report date 2026-07-15 | $25.06B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-15.eps_actual | EPS · reported — report date 2026-07-15 | $2.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-15.eps_estimated | EPS · estimate — report date 2026-07-15 | $2.8400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-14.revenue_actual | Revenue · reported — report date 2026-04-14 | $24.06B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-14.revenue_estimated | Revenue · estimate — report date 2026-04-14 | $23.61B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-14.eps_actual | EPS · reported — report date 2026-04-14 | $2.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-14.eps_estimated | EPS · estimate — report date 2026-04-14 | $2.6800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-21.revenue_actual | Revenue · reported — report date 2026-01-21 | $24.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-21.revenue_estimated | Revenue · estimate — report date 2026-01-21 | $24.15B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-21.eps_actual | EPS · reported — report date 2026-01-21 | $2.4600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-21.eps_estimated | EPS · estimate — report date 2026-01-21 | $2.4600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-14.revenue_actual | Revenue · reported — report date 2025-10-14 | $23.99B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-14.revenue_estimated | Revenue · estimate — report date 2025-10-14 | $23.76B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-14.eps_actual | EPS · reported — report date 2025-10-14 | $2.8000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-14.eps_estimated | EPS · estimate — report date 2025-10-14 | $2.7600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $20.76B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $4.71B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-28. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $49.04B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 7.32× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-28.operating_cash_flow_m | Operating cash flow — period end 2026-06-28 | $4.71B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-29.operating_cash_flow_m | Operating cash flow — period end 2026-03-29 | $2.51B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-28.capex_m | Capital expenditure (reported) — period end 2026-06-28 | −$1.32B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-29.capex_m | Capital expenditure (reported) — period end 2026-03-29 | −$1.05B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-28.operating_cash_flow_m | Operating cash flow — period end 2025-12-28 | $7.31B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-28.capex_m | Capital expenditure (reported) — period end 2025-12-28 | −$1.84B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.operating_cash_flow_m | Operating cash flow — period end 2025-09-28 | $9.17B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.capex_m | Capital expenditure (reported) — period end 2025-09-28 | −$788.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $255.00 – $320.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 7, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $286.53 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 7, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $282.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 7, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 46 transactions · 0 purchases, 10 sales, 36 other transactions · 18 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 8, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 74.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 73.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 4,810 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 4,764 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 212,098,264 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 157,226,374 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 133,776,025 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 64,370,816 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Geode Capital Management, LLC — shares in provider snapshot | 59,086,417 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 13, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-07-18 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 29.58× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $20.76B at Jun 28, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-06. Balance-sheet reference date: 2026-06-28. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $5.28 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-06, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.07% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-15.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($25.31B) with the recorded estimate ($25.06B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-15.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($2.9000) with the recorded estimate ($2.8400) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 89 of 100 · Exceptional · pillars 92 / 73 / 46 / 87 / 76 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 90 (stored snapshot Oct 6, 2026) → 89 (current publication computed Oct 7, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-28. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-28.revenue_k,fin.q_table.depth.2026-06-28.rd_k,fin.q_table.depth.2026-06-28.sga_k,fin.q_table.depth.2026-06-28.operating_result_k,fin.q_table.depth.2026-03-29.revenue_k,fin.q_table.depth.2026-03-29.rd_k,fin.q_table.depth.2026-03-29.sga_k,fin.q_table.depth.2026-03-29.operating_result_k,fin.q_table.depth.2025-12-28.revenue_k,fin.q_table.depth.2025-12-28.rd_k,fin.q_table.depth.2025-12-28.sga_k,fin.q_table.depth.2025-12-28.operating_result_k,fin.q_table.depth.2025-09-28.revenue_k,fin.q_table.depth.2025-09-28.rd_k,fin.q_table.depth.2025-09-28.sga_k,fin.q_table.depth.2025-09-28.operating_result_k. - Earnings-history note. Source series as of 2026-07-15. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-15.revenue_actual,earn.history.depth.2026-07-15.revenue_estimated,earn.history.depth.2026-07-15.revenue_actual.comparison,earn.history.depth.2026-07-15.eps_actual.comparison,earn.history.depth.2026-07-15.eps_actual,earn.history.depth.2026-07-15.eps_estimated,earn.history.depth.2026-04-14.revenue_actual,earn.history.depth.2026-04-14.revenue_estimated,earn.history.depth.2026-04-14.eps_actual,earn.history.depth.2026-04-14.eps_estimated,earn.history.depth.2026-01-21.revenue_actual,earn.history.depth.2026-01-21.revenue_estimated,earn.history.depth.2026-01-21.eps_actual,earn.history.depth.2026-01-21.eps_estimated,earn.history.depth.2025-10-14.revenue_actual,earn.history.depth.2025-10-14.revenue_estimated,earn.history.depth.2025-10-14.eps_actual,earn.history.depth.2025-10-14.eps_estimated. - Cash-flow note. Source series as of 2026-06-28. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-28.operating_cash_flow_m,fin.opcf.depth.2026-03-29.operating_cash_flow_m,fin.opcf.depth.2026-06-28.capex_m,fin.opcf.depth.2026-03-29.capex_m,fin.opcf.depth.2025-12-28.operating_cash_flow_m,fin.opcf.depth.2025-12-28.capex_m,fin.opcf.depth.2025-09-28.operating_cash_flow_m,fin.opcf.depth.2025-09-28.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Med Tech: $33.79B; Innovative Medicine: $60.40B | 2025-12-28 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-15 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-07-23 | OFFICIAL | SEC EDGAR filer submissions | |
| Management outlook — dated call excerpts | Captured record · 1 entry
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-15 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash, investments and debt | Total debt: $49.04B; Liquidity basis: cash and short-term investments; Total liabilities: $116.09B; Cash and short-term investments: $20.76B; Cash and investments: $20.76B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Trailing twelve-month ratio set | Quick ratio: 0.81; Current ratio: 1.09; Debt to equity: 0.58; Net margin: 21.5%; Gross margin: 70.5%; Operating margin: 26.8%; Return on assets: 10.5%; Return on equity: 25.7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 5.45; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-08-25 | FMP | Financial Modeling Prep (FMP) dividend history |
| Next earnings report | Date: 2026-10-13; EPS estimate: $2.9 per share; Revenue estimate: $25.33B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold JNJ
Funds in our ETF coverage that list JNJ among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Evolved U.S. Innovative Healthcare ETF (IEIH) | 10.24% | |
| PBPH ETF | 9.35% | |
| VHT ETF | 8.22% | |
| ProShares - Ultra Health Care (RXL) | 7.33% | |
| IXJ ETF | 7.22% | |
| Brookstone Value Stock ETF (BAMV) | 4.64% | |
| iShares MSCI USA Momentum Factor ETF (MTUM) | 4.53% | |
| Simplify Health Care ETF (PINK) | 4.48% | |
| GVLE ETF | 3.67% | |
| Nuveen Sustainable Core (NSCR) | 3.63% |